CD20 in Disease Therapy

Dear Colleagues,

CD20 is a non-glycosylated transmembrane protein expressed on a variety of B-cells from the pre-B-cell stage to mature/memory B cells, but not plasma cells. CD20 mAb against human CD20 induce rapid B-cell depletion and is currently approved by the Food and Drug Administration (FDA) for treatment of non-Hodgkin B-cell lymphomas and several autoimmune disorders including type I diabetes (T1D), rheumatoid arthritis, and Sjogren’s syndrome (SS). The immediate short- or prolonged-action mechanisms of anti-CD20 in depleting B-cells are through the direct induction of apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent lysis (CDC) which are used for immunotherapy, immunization effect as well as immune tolerance applications. As CD20 mAb becomes involved in broad aspects of disease therapies and immunomodulation, understanding the detailed functions as well as their subsequent mechanisms will provide insights into the development of translational applications. Primary research manuscripts or review articles related to various aspects of CD20 mAb in therapies are invited for this Special Issue.

Dr. Chao lien Liu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medical Sciences is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• CD20 mAb therapy
• B-cell depletion
• Anti-CD20 immunotherapy
• B-cell tolerance
• B-cell immune responses
• CD20 mAb treatment mechanisms
• Anti-CD20 compounds
• Anti-CD20 immunization effects
• B-cell lymphomas
• B-cell targeted therapies